Last reviewed · How we verify
Permethrin 5%
Permethrin 5% is a marketed product developed by Barzilai Medical Center, positioned in the dermatological segment. The key composition patent expires in 2028, providing a strong barrier to generic competition until then. The primary risk is the lack of revenue data, which limits visibility into the drug's commercial performance and market share.
At a glance
| Generic name | Permethrin 5% |
|---|---|
| Sponsor | Barzilai Medical Center |
| Drug class | Pyrethroid [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
- Burning and stinging
- Pruritus
- Erythema
- Rash
- Numbness
- Tingling
- Headache
- Fever
- Dizziness
- Abdominal pain
- Diarrhea
- Nausea and/or vomiting
Serious adverse events
- Seizure
Key clinical trials
- Comparison of Permethrin-Based Treatment Strategies Against Scabies in Infants and Young Children (EARLY_PHASE1)
- Ivermectin Safety in Small Children (PHASE2)
- Better Options for Lymphatic Filariasis Treatment (PHASE3)
- Comparison of Permethrin and Ivermectin in Children Greater Than 6 Yrs Age for Treatment of Scabies (PHASE2)
- Long-term Follow-up of Children Born in the PETN Studies
- Oral Ivermectin Versus Topical Permethrin to Treat Scabies in Children and Adults (PHASE3)
- Sulfur vs. Different Regimes of Permethrin for Scabies (PHASE3)
- Therapy for Scabies With Two Differently Concentrated Permethrin Creams (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Permethrin 5% CI brief — competitive landscape report
- Permethrin 5% updates RSS · CI watch RSS
- Barzilai Medical Center portfolio CI